3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma AVIR

Atea Pharmaceuticals, Inc.

AVIR NASDAQ Biotech & Pharma

Stock factsheet

TickerAVIR
ExchangeNASDAQ
ISIN
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 376 Mio. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

Atea Pharmaceuticals is a clinical-stage biotechnology company developing antiviral medicines against RNA viruses. The research programme includes candidates targeting hepatitis C, COVID-19 and other viral diseases, based on nucleotide polymerase inhibitor chemistry. The company has no approved products to date.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
Atea Pharmaceuticals, Inc.AVIR NASDAQ376 Mio. USD
X4 Pharmaceuticals, Inc. XFORNASDAQ 375 Mio. USD
Emergent BioSolutions Inc. EBSNYSE 373 Mio. USD
Mobia Medical, Inc. MOBINASDAQ 372 Mio. USD
Evolus, Inc. EOLSNASDAQ 385 Mio. USD
C4 Therapeutics, Inc. CCCCNASDAQ 385 Mio. USD
Enanta Pharmaceuticals, Inc. ENTANASDAQ 366 Mio. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.